Related Experiment Video

Updated: Aug 11, 2026

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Use of novel second-line targeted therapies in non-small cell lung cancer

Erminia Massarelli1, Roy S Herbst

  • 1Department of Thoracic/Head and Neck Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA.

Seminars in Oncology
|February 14, 2006
PubMed

Insights

New targeted therapies show promise for advanced non-small cell lung cancer (NSCLC). Agents blocking EGFR or angiogenesis offer improved outcomes for patients with refractory disease.

Area of Science:

  • Oncology
  • Medical Science

Background:

  • Non-small cell lung cancer (NSCLC) is a leading cause of cancer mortality globally.
  • Metastatic disease at diagnosis limits curative local treatment options for over half of NSCLC patients.
  • Current standard cytotoxic chemotherapy for NSCLC has limitations, necessitating novel approaches for refractory cases.

Purpose of the Study:

  • To review advancements in NSCLC treatment, focusing on molecular targeted therapies.
  • To evaluate the efficacy of epidermal growth factor receptor (EGFR) inhibitors and angiogenesis inhibitors in refractory NSCLC.
  • To assess the potential of these targeted agents in improving survival and quality of life.

Main Methods:

  • Literature review of recent clinical studies on NSCLC treatment.
  • Analysis of response rates for EGFR-targeted agents (gefitinib, erlotinib, cetuximab).
  • Evaluation of outcomes for angiogenesis inhibitors (bevacizumab, ZD6474) in combination regimens.

Main Results:

  • EGFR inhibitors demonstrated overall response rates of 18.4% (gefitinib), 8.9% (erlotinib), and 3.3% (cetuximab).
  • Angiogenesis inhibitors showed promise: bevacizumab (27% response rate with paclitaxel/carboplatin) and ZD6474 (26% response rate with docetaxel).
  • These targeted therapies represent significant progress in managing advanced and refractory NSCLC.

Conclusions:

  • Molecular targeted therapies, including EGFR and angiogenesis inhibitors, offer new avenues for treating refractory NSCLC.
  • Combination strategies involving these agents may enhance patient survival and quality of life.
  • Continued research into targeted therapies is crucial for improving outcomes in NSCLC.

More Related Videos

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...